menu ☰
menu ˟

FDA grants Jakafi breakthrough designation to treat acute GVHD

23 Jun 2016
The FDA granted ruxolitinib breakthrough therapy designation for the treatment of patients with acute graft-versus-host disease.No therapy is currently FDA–approved for acute GVHD. ...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.